Tango Therapeutics Inc

Canaccord Genuity raised its price target on Tango Therapeutics from $42 to $46 while Jefferies upgraded the stock from Hold to Buy and lifted its target from $27 to $60, citing the potential of vopimetostat combined with KRAS inhibitors. Canaccord's revised model incorporates combined revenues from the therapy in non-small cell lung cancer, while Jefferies highlighted promising data for vopimetostat plus daraxonrasib in pancreatic ductal adenocarcinoma, estimating an opportunity worth more than $4 billion covering 25% to 40% of patients. Tango Therapeutics also recently signed an underwriting agreement for an offering of nearly 18.2 million common shares at $30 per share and pre-funded warrants for over 1.83 million shares at $29.99, expecting net proceeds of around $566.5 million to fund pivotal trials and other corporate needs.

Tango Therapeutics is emerging as a key test of precision oncology's value in 2026, centered on MTAP-deleted cancers and synthetic lethality. Its lead asset vopimetostat, an MTA-cooperative PRMT5 inhibitor, is being combined with Revolution Medicines' daraxonrasib and zoldonrasib, as well as Erasca's pan-RAS molecular glue ERAS-0015, in MTAP-deleted, RAS-mutant pancreatic cancer. An early signal from the vopimetostat-daraxonrasib arm showed a 92% objective response rate, 100% disease control rate, and 90% six-month progression-free survival rate among 12 evaluable patients, with plans to advance into late-stage development. Vopimetostat is also in monotherapy studies for MTAP-deleted lung cancer, while brain-penetrant TNG456 is in a phase I/II trial for MTAP-deleted solid tumors including glioblastoma, with data expected in 2026. The stock carries a Zacks Rank #3 (Hold) and a Momentum Score of B, though value and growth scores remain weak.

Tango Therapeutics has appointed Robert Azelby to its Board of Directors. Azelby brings more than 30 years of experience in executive management, commercial product launches, and corporate governance, and currently serves on the boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health. He previously served as President and CEO of Eliem Therapeutics and as CEO and board member of Alder BioPharmaceuticals. Tango is advancing its investigational PRMT5 inhibitor, Vopimetostat, through late-stage development for pancreatic cancer. Shares of Tango closed Monday at $28.50, up 1.89%, and were trading at $28.49 in the pre-market.